InnoCare Pharma Limited reported minimal equity movement for September 2026, with total issued shares edging up by 0.58 million to 1.77 billion across its dual listings in Hong Kong and on Shanghai’s STAR Market. The uptick reflects the issuance of 581,137 new A-shares under the 2024 RMB Share Incentive Scheme at RMB 6.65 per share. No Hong Kong-listed shares were issued or repurchased during the period, and treasury shares were unchanged at 2.49 million.

Authorised capital stayed constant at 25.00 billion ordinary shares with a par value of USD 0.000002, translating into authorised share capital of USD 50,000. As at 30 September 2026, Hong Kong-listed ordinary shares in issue (excluding treasury) totalled 1.49 billion, while STAR Market shares stood at 273.40 million.

InnoCare confirmed full compliance with the Hong Kong Stock Exchange’s 25% minimum public-float requirement. The company’s current share-based compensation programmes still allow for future issuances: up to 2.47 million shares under the 2023 RMB Share Incentive Scheme, 9.18 million under the 2024 plan, and 8.00 million under the 2026 plan remain available. No options, warrants, or convertible securities were outstanding or exercised during the month.

Overall, the September filing indicates a stable capital structure, with share count changes limited to incentive-related issuances and no impact on treasury share levels.